Step 1 topics → Hematology and Oncology → DLBCL and Follicular Lymphoma

DLBCL and Follicular Lymphoma

USMLE Step 1 trap: Confuses follicular lymphoma's t(14;18)/BCL-2 with Burkitt's t(8;14)/MYC. Follicular lymphoma is driven by t(14;18), which juxtaposes BCL-2 to the IgH locus, causing BCL-2 overexpression and failure of apoptosis; t(8;14) drives Burkitt lymphoma.

DLBCL and follicular lymphoma are the two most common non-Hodgkin lymphomas, and USMLE Step 1 tests them as a pair precisely because students confuse their translocations, behaviors, and treatment. DLBCL is aggressive and potentially curable; follicular lymphoma is indolent but incurable with standard therapy. The exam will give you a clinical vignette and ask you to identify the diagnosis, explain the molecular mechanism, or select the correct treatment — so you need the full picture for both, not just scattered facts.

The trickiest part is the translocation mapping. Students frequently swap t(14;18)/BCL-2 (follicular) with t(8;14)/MYC (Burkitt), especially under pressure. Both involve chromosome 14's IgH locus, which is why they feel interchangeable — but the partner chromosome and the resulting oncogene are completely different. On top of that, students routinely write CHOP for DLBCL and forget rituximab, which has been standard of care for decades.

There's also a high-yield clinical scenario that many students miss entirely: follicular lymphoma transforming into DLBCL. USMLE Step 1 can present a patient with known indolent lymphoma who suddenly develops rapid lymph node growth, elevated LDH, and B symptoms — that's transformation, and it changes the entire management strategy. Recognizing this shift from indolent to aggressive disease is exactly the kind of application-level reasoning the exam rewards.

From real student decks
68%have cards covering this topic
43%have mature cards
1median lapses in 14 days

Common misconceptions

Common mistake
Wrong: Follicular lymphoma is driven by the t(8;14) MYC translocation.
Right: Follicular lymphoma is driven by t(14;18), which juxtaposes BCL-2 to the IgH locus, causing BCL-2 overexpression and failure of apoptosis; t(8;14) drives Burkitt lymphoma.
Both follicular lymphoma and Burkitt lymphoma involve chromosome 14's immunoglobulin heavy chain (IgH) locus, which is why students mix them up — but the partner differs critically. Follicular lymphoma uses t(14;18), dragging BCL-2 (an anti-apoptotic protein) next to IgH, so B cells that should die instead survive indefinitely. Burkitt lymphoma uses t(8;14), placing MYC (a proliferation driver) next to IgH, producing explosive cell growth — a completely different mechanism with a completely different clinical behavior.
Common mistake
Wrong: DLBCL is treated with CHOP alone without a monoclonal antibody.
Right: Standard first-line treatment for DLBCL is R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisone), with rituximab targeting CD20.
CHOP alone was the standard decades ago, but rituximab — an anti-CD20 monoclonal antibody — was added after trials showed dramatically improved outcomes, making R-CHOP the current standard for DLBCL. Since DLBCL is a mature B-cell lymphoma, its cells express CD20, giving rituximab a clear target. On Step 1, writing CHOP without the R is a factual error; the exam expects you to know both the regimen and the mechanism of rituximab's action.
Common mistake
Gap: Missing that follicular lymphoma can transform into aggressive DLBCL, signaled by rapid clinical deterioration
Follicular lymphoma can transform into DLBCL (Richter-like transformation), which is heralded by sudden rapid lymph node enlargement, elevated LDH, and worsening B symptoms.
Follicular lymphoma is indolent by nature — patients can have stable, slowly growing disease for years. But in roughly 30% of cases, it undergoes histologic transformation into DLBCL (sometimes called Richter-like transformation), which is signaled clinically by sudden rapid lymph node enlargement, a spike in LDH, new or worsening B symptoms (fever, night sweats, weight loss), and a patient who simply looks sicker faster than expected. This transformation matters because it converts a 'watch and wait' situation into an urgent aggressive-lymphoma treatment scenario, and the Step 1 exam can test whether you recognize that clinical pivot.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know the epidemiology (most common aggressive NHL in adults), classic presentation (rapidly enlarging lymphadenopathy ± B symptoms), and first-line treatment (R-CHOP) for DLBCL — the exam tests all three angles.
  2. Understand the molecular mechanism of follicular lymphoma: t(14;18) juxtaposes BCL-2 to the IgH locus, driving BCL-2 overexpression, blocking apoptosis, and producing an indolent but persistent lymphoma — and know how this differs from Burkitt's t(8;14)/MYC.

Can you avoid these mistakes?

A 58-year-old man presents with a rapidly enlarging neck mass, fever, and 10-pound weight loss over 2 months. Biopsy shows large B cells diffusely replacing the lymph node architecture. What is the diagnosis, and what is the standard first-line treatment — name all components and explain why each is included?
What is the specific chromosomal translocation in follicular lymphoma, which two genes are involved, and what is the functional consequence at the protein level that explains why these lymphomas are indolent rather than rapidly proliferative?
A patient diagnosed with follicular lymphoma 6 years ago, previously stable on watchful waiting, now presents with a 3-week history of rapidly enlarging inguinal lymphadenopathy, drenching night sweats, and a new LDH of 520 U/L. What has likely happened, and how does this change management?
Your classmate says follicular lymphoma and Burkitt lymphoma both involve chromosome 14, so they must have the same translocation. Walk through why this reasoning is wrong — what are the actual translocations, which oncogenes are involved, and how do the resulting diseases differ in behavior?

Related topics

Leukemia vs Lymphoma Framework Hematopoiesis and Lineage Differentiation RBC Physiology and Lifespan WBC Differential and Function Platelet Physiology and Primary Hemostasis

See how your Anki deck covers this topic.

Upload your deck for a free audit →